Business
MEDIPAL HOLDINGS and JCR Pharmaceuticals Sign Global Licensing and Japan Co-Development Agreement for JR-479, a Novel Therapy for GM2 Gangliosidosis
TOKYO & HYOGO, Japan, September 02, 2025--JCR and MEDIPAL announced an exclusive global licensing deal and a co-development and commercialization partnership in Japan for JR-479.
About this update from Medipal Holdings Corporation
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1289,"height":503,"url":"https://media.zenfs.com/en/business-wire.com/d83a0ec665ca7c832f0a643ecb4b8b1a"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/l6.giUmzrlQa54pShMDQ7w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTM3NTtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/d83a0ec665ca7c832f0a643ecb4b8b1a","width":960,"height":375},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/jHnbxH4pwB9IqeYLXVKvfg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD05MzY7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/d83a0ec665ca7c832f0a643ecb4b8b1a","width":1200,"height":468}},"lazy":false},{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1024,"height":512,"url":"https://media.zenfs.com/en/business-wire.com/cf3241719d3c1a62ecdc117d5e129160"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/YutPYpMhTkPXSH6XhUZsVQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQ4MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/cf3241719d3c1a62ecdc117d5e129160","width":960,"height":480},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/UHafIN4zk.7dMuj_HLU8ZQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIwNDg7aD0xMDI0O2NmPXdlYnA-/https://media.zenfs.com/en/business-wire.com/cf3241719d3c1a62ecdc117d5e129160","width":1024,"height":512}}},{"type":"text","content":"TOKYO & HYOGO, Japan, September 02, 2025--(BUSINESS WIRE)--MEDIPAL HOLDINGS CORPORATION (TSE 7459, MEDIPAL) and JCR Pharmaceuticals Co., Ltd. (TSE 4552, JCR) announced that the two companies have signed an exclusive global licensing deal and a co-development and commercialization partnership in Japan for JR-479, an investigational therapy for GM2 gangliosidosis, an ultra-rare lysosomal storage disorder.","length":410,"tagName":"p"},{"type":"text","content":"GM2 gangliosidoses are a group of rare, inherited disorders caused by genetic mutations that prevent the normal breakdown of GM2 gangliosides in lysosomes, leading to their buildup, especially in neurons. Tay-Sachs disease and Sandhoff disease are the two most common types of GM2 gangliosidosis depending on the specific mutation. GM2 gangliosidosis affects an estimated one in 300,000 people worldwide and is considered an ultr...